|
NEW YORK, Sept. 10 (Xinhua) -- China's Vcanbio Cell & Gene Engineering Corporation, Ltd. on Saturday formally announced the operation of its two branches in the United States, marking the establishment of its North America headquarters.
The company's two subsidiaries, Vcanbio USA Co. Ltd. and Vcanbio Center for Translational Biotechnology (CBT), are both located in Natick, in the northeastern U.S. state of Massachusetts.
"Boston area is the most innovative center of biotech in the world. A number of well-known research institutes, universities, hospitals and biotech companies are located around this area. By establishing the two subsidiaries here, it will enable us to access the state-of-the-art technology and information," Chief Executive Officer of Vcanbio Wu Mingyuan said at the opening ceremony.
Vcanbio USA focuses on investing in cell and immunotherapy areas in North America. The CBT's major goal is to function as a service entity, aiming to foster the advance of promising biologics, treatments and new therapies, through partnership and co-development.
Wu expects they will help enhance cooperation and exchanges between China and the United States in the biotech sector.
Vcanbio's important work in the field of cell therapy and precision medicine will be supported by a high-caliber workforce, world-class universities, like-minded companies and a state government that fosters a pro-business environment, said Mark Sullivan, executive director of Massachusetts Office of International Trade & Investment.
